Cargando…
Differential Effects of Selective Inhibitors Targeting the PI3K/AKT/mTOR Pathway in Acute Lymphoblastic Leukemia
PURPOSE: Aberrant PI3K/AKT/mTOR signaling has been linked to oncogenesis and therapy resistance in various malignancies including leukemias. In Philadelphia chromosome (Ph) positive leukemias, activation of PI3K by dysregulated BCR-ABL tyrosine kinase (TK) contributes to the pathogenesis and develop...
Autores principales: | Badura, Susanne, Tesanovic, Tamara, Pfeifer, Heike, Wystub, Sylvia, Nijmeijer, Bart A., Liebermann, Marcus, Falkenburg, J. H. Frederik, Ruthardt, Martin, Ottmann, Oliver G. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3828226/ https://www.ncbi.nlm.nih.gov/pubmed/24244612 http://dx.doi.org/10.1371/journal.pone.0080070 |
Ejemplares similares
-
A phase I study of a dual PI3-kinase/mTOR inhibitor BEZ235 in adult patients with relapsed or refractory acute leukemia
por: Lang, Fabian, et al.
Publicado: (2020) -
Oncogene-independent resistance in Philadelphia chromosome - positive (Ph(+)) acute lymphoblastic leukemia (ALL) is mediated by activation of AKT/mTOR pathway
por: Mian, Afsar Ali, et al.
Publicado: (2021) -
PI3K/AKT/mTOR Pathway in Angiogenesis
por: Karar, Jayashree, et al.
Publicado: (2011) -
Targeting PI3K/Akt/mTOR Signaling in Cancer
por: Porta, Camillo, et al.
Publicado: (2014) -
PI3K/Akt/mTOR inhibitors in breast cancer
por: Lee, Joycelyn JX, et al.
Publicado: (2015)